Clover BioPharmaceuticals

Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China
Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China
BioSpace
Clover BioPharmaceuticals
China
COVID-19
vaccines
boosters
Flag link:
Clover touts phase 3 omicron data as wait for COVID-19 vaccine approvals drags on
Clover touts phase 3 omicron data as wait for COVID-19 vaccine approvals drags on
Fierce Biotech
Clover BioPharmaceuticals
COVID-19
vaccines
boosters
clinical trials
Flag link:
Clover’s COVID-19 Booster Vaccine Candidate Demonstrates Robust Neutralization of Dominant Omicron BA.5
Clover’s COVID-19 Booster Vaccine Candidate Demonstrates Robust Neutralization of Dominant Omicron BA.5
BioSpace
Clover BioPharmaceuticals
vaccines
boosters
COVID-19
Flag link:
Clover Announces Positive Phase 2/3 Results in Adolescents for its COVID-19 Vaccine
Clover Announces Positive Phase 2/3 Results in Adolescents for its COVID-19 Vaccine
BioSpace
Clover BioPharmaceuticals
vaccines
COVID-19
teens
Flag link:
Clover Biopharmaceuticals sets up a new R&D center in a buzzy Chinese hub near Shanghai
Clover Biopharmaceuticals sets up a new R&D center in a buzzy Chinese hub near Shanghai
Endpoints
Clover BioPharmaceuticals
China
R&D
Flag link:
Can Clover’s Vaccine Candidate Stand Its Ground Against COVID Variants?
Can Clover’s Vaccine Candidate Stand Its Ground Against COVID Variants?
BioSpace
Clover BioPharmaceuticals
COVID-19
vaccines
SCB-2019
COVID-19 variants
Flag link:
Clover's COVID-19 shot tames delta in pivotal study, delivering boost to global vaccination campaign
Clover's COVID-19 shot tames delta in pivotal study, delivering boost to global vaccination campaign
Fierce Biotech
Clover BioPharmaceuticals
COVID-19
vaccines
SCB-2019
clinical trials
Flag link:
Clover raises $230M as COVID-19 vaccine nears phase 3, multivariant prospect gets going
Clover raises $230M as COVID-19 vaccine nears phase 3, multivariant prospect gets going
Fierce Biotech
Clover BioPharmaceuticals
COVID-19
vaccines
clinical trials
Flag link:
Biotech partner drops GlaxoSmithKline’s adjuvant as it moves Covid-19 vaccine into PhII/III, citing ‘manufacturing considerations’
Biotech partner drops GlaxoSmithKline’s adjuvant as it moves Covid-19 vaccine into PhII/III, citing ‘manufacturing considerations’
Endpoints
GSK
vaccines
Clover BioPharmaceuticals
adjuvants
Flag link:
Clover nears pivotal trial of GSK-adjuvanted COVID-19 vaccine
Clover nears pivotal trial of GSK-adjuvanted COVID-19 vaccine
Fierce Biotech
Clover BioPharmaceuticals
clinical trials
COVID-19
vaccines
GSK
Flag link:
Using GSK and Dynavax tech, Clover kick-starts COVID-19 vax trial with data drop in August
Using GSK and Dynavax tech, Clover kick-starts COVID-19 vax trial with data drop in August
Fierce Biotech
GSK
Dynavax
Clover BioPharmaceuticals
vaccines
COVID-19
Flag link:
A Chinese biotech partners with GSK to boost its coronavirus vaccine development
A Chinese biotech partners with GSK to boost its coronavirus vaccine development
Stat
China
GSK
vaccines
coronavirus
Clover BioPharmaceuticals
Flag link:
Clover Initiates Ph I Study of Enbrel Biosimilar in China
Clover Initiates Ph I Study of Enbrel Biosimilar in China
CP Wire
Clover BioPharmaceuticals
Enbrel
Amgen
biosimilars
SCB-808
China
Flag link:
Clover Initiates Ph I Study of Enbrel Biosimilar in China
Clover BioPharmaceuticals
SCB-808
Enbrel
generics
Flag link:
Chinese drugmakers tap GE tech, seeing biologic boom ahead
Chinese drugmakers tap GE tech, seeing biologic boom ahead
Biopharma Dive
China
biologics
GE Healthcare
Clover BioPharmaceuticals
Flag link: